The aim of the current study is to assess the association between the alleles of endothelial nitric oxide synthases (eNOS) gene 4b/a, G894T, T786C polymorphisms and diabetic nephropathy (DN) through meta-analyses. We also performed a subgroup analysis based on ethnicity (Caucasians, East-Asian and other populations). A total of 3793 patients (DN) and 3161 controls (diabetes without nephropathy) for 4b/a, 2654 patients and 1993 controls for G894T and 1348 patients and 1175 controls for T786C were included in our analysis. Overall, allele contrast (4a versus 4b) of 4b/a polymorphism produced significant results in the global population [random effects model (RE) odds ratio (OR) 5 1.33; 95% confidence interval (CI) 5 1.10-1.61, P 5 0.003] and East-Asian population (RE OR 5 1.68; 95% CI 5 1.23-2.30, P 5 0.001), but not in the Caucasian population. In allele contrast of G894T, an obvious significant result was observed in the East-Asian population [fixed effects model OR 5 1.69; 95% CI 5 1.37-2.08, P < 0.0001], but not in the Caucasian population. Sensitivity analyses generated similar results to those of the primary analyses. The evidence accumulated suggested that 4b/a and G894T polymorphisms in the eNOS gene were associated with susceptibility to DN in Asian populations, but not in Caucasian populations.
Introduction
Diabetic nephropathy (DN) is one of the most serious complications of diabetes with morbidity as high as 20-40% (1) . DN is the leading cause of end-stage renal disease over the world and is the second cause of blood dialysis in China (13.5%). Long-term exposure to a hyperglycaemic environment, obesity, hypertension and hyperlipidaemia contribute to the pathogenesis of DN. As more and more pedigree analyses have suggested that DN is also influenced by genetic variants among metabolic-related genes (2) (3) (4) , it is widely accepted that individuals with diabetes may be at different levels of susceptibility to nephropathy. Many genes have been reported to be associated with DN, such as angiotensin-converting enzyme (ACE) (5) , endothelial nitric oxide synthases (eNOS), superoxide dismutase2 (6) , among which eNOS has been emphasised a lot because endothelial dysfunction has been shown to be an important pathophysiologic denominator for DN. In vivo studies have shown that increased amounts of eNOS (encoded by the NOS3 gene) have been found in preglomerular vessels in diabetic rat glomeruli, and nitric oxide synthases (NOS) inhibitors have been shown to prevent an increase in the glomerular filtration rate. This suggests that NOS contribute to the glomerular damage leading to nephropathy in diabetic patients.
NOS have three distinct isoforms according to their activity or the tissue type in which they were first described, including type 1 or neuronal NOS (nNOS), type 2 or inducible NOS (iNOS) and type 3 or endothelial NOS (eNOS), among which eNOS plays a key role in the regulation of vascular function including DN (7) . The eNOS gene is located on chromosome 7q35-36 and comprises 26 exons that span 21 kb and is expressed mainly in the endothelium. The eNOS gene encodes a protein composed of 1204 amino acids with the size of $1.5 kDa. Limited proteolysis at the calmodulin-binding site is able to cleave the protein into the C-terminal region and the Nterminal region. The C-terminal region contains flavin mononucleotide, flavine-adenine dinucleotide and reduced form of nicotinamide-adenine dinucleotide phosphate (NADPH)-binding regions, whereas the N-terminal region contains the oxygenase fragment and the arginine-binding site, BH4 and heme. eNOS can be phosphorylated through PI3-K/Akt pathway and is mainly involved in the pathway of AkteNOS-NO and cyclic guanosine monophosphate generation. eNOS has vasoprotective effects by scavenging superoxide radicals and suppressing platelet aggregation, leucocyte adhesion and smooth muscle cell proliferation. Moreover, the expression of eNOS is altered in many types of vascular disease, such as artherosclerosis, diabetes, hypertension and DN. Recent studies suggest that dysfunctional eNOS may play a critical role in the pathogenic pathway, leading to diabetic vascular complications including DN (8) .
There are numerous studies focussing on genetic polymorphisms and DN. Three eNOS polymorphisms, the Intron 4 27-bp repeat (4b/a), the G894T (Glu298Asp) missense mutation in exon 7 and the T786C single-nucleotide polymorphism in the promoter region have been studied. T786C reduces eNOS transcription (9); G894T may be associated with a decrease of eNOS activity (10, 11) and 4b/a polymorphism has been reported to be associated with decreased plasma nitric oxide (NO) concentrations that may reflect the activity of eNOS (12) .
These polymorphisms were all reported to be associated with coronary artery disease and nephropathy (13) (14) (15) . However, the association between DN risk and polymorphisms found in eNOS is still controversial. Some researchers (16, 17) have found that different genotypes of eNOS were associated with DN, whereas results obtained by other researchers (18, 19) suggest that they may not be significantly associated with DN risk. These studies were all based on a limited sample size and sometimes on samples of different ethnicities. Therefore, every single study may be inadequate in achieving a comprehensive and reliable conclusion. To better address the association between eNOS polymorphisms and DN risk, we performed a meta-analysis from all eligible studies, including subgroup analyses based on samples of different ethnicities.
Subjects and methods

Search strategy
All eligible studies were identified by searching the PubMed database for related reports published before November 2009 using the following search criterion: ('polymorphism' or 'polymorphisms') and ('endothelial nitric oxide synthase' or 'nitric oxide synthase' or NOS or eNOS or ecNOS or 'ecNOS4' or 'NOS3') and ('diabetic nephropathy' or 'diabetic renal disease'). References of retrieved articles were also screened. Articles reporting the association between DN and eNOS polymorphisms were identified. Studies included had to meet all the following criteria: (i) based on unrelated individuals, pedigree data were excluded; (ii) genotype distributions in both patients and controls were available and (iii) the genotype distribution of the control population must be in Hardy-Weinberg equilibrium (HWE).
Data extraction
Two investigators collected the data independently and reached a consensus on all items. The following basic information was extracted from the eligible studies: first author, year of publication, ethnicity of population studied, sample size, type of sample for genotyping, gender, age and other variables that can be sources of bias. Genotype distribution in both cases and controls were also obtained.
Statistical analysis
Meta-analysis. Odds ratios (OR) corresponding to a 95% confidence interval (CI) were used to assess the strength of association between eNOS polymorphisms and DN. Unadjusted OR of each study was first calculated in a 2 Â 2 table. The meta-analysis examined the association between eNOS and DN risk compared with that for per-allele model (4a vs 4b for 4b/a, T vs G for G894T, C vs T for T786C ), dominant model (4aa þ 4ba vs 4bb for 4b/a, TT þ GT vs GG for G894T, CC þ TC vs TT for T786C), recessive model (4aa vs 4ba þ 4bb for 4b/a, TT vs GTþGG for G894T, CC vs TC þ TT for T786C), extreme model (4aa vs 4bb for 4b/a, TT vs GG for G894T, CC vs TT for T786C), a/A model (4a vs 4b for 4b/a, T vs G for G894T, C vs T for T786C), Aa/AA model (4ba vs 4bb for 4b/a, GT vs GG for G894T, TC vs TT for T786C) and aa/ Aa model (4aa vs 4ba for 4b/a, TT vs GT for G894T, CC vs TC for T786C). Between-study heterogeneity was assessed by a chi-square-based Q-statistic test according to Lau et al. (20) .
Heterogeneity was considered significant when P ,0.10. A random effects (RE) model using the DerSimonian and Laird method and a fixed effects (FE) model using the MantelHaenszel method were usually used to pool the results. Two methods produced similar results in the absence of heterogeneity. The RE model was more appropriate when a significant heterogeneity was present. Both the FE and RE models were used in Review-Manager 4.2 software, and pooled OR under both models was presented for a clearer comparison. The significance of pooled OR was tested by Z test (P , 0.05 was considered significant).
Population stratification. For eNOS contrasts, subgroup analyses according to ethnicity (Caucasians, East-Asians and others) and DN were performed to estimate OR in specific populations.
Sensitivity analysis. Through sequential omission of individual studies under various contrasts in Caucasian and East-Asian subgroups, respectively, a sensitivity analysis was performed.
Assessment of publication bias. Funnel plots were used to investigate publication bias, where standard error of log (OR) of each study was plotted against its OR. Funnel plot asymmetry was assessed by the method of Egger's linear regression test, a linear regression approach to measure funnel plot asymmetry on the natural logarithm scale of the OR (21) . The significance of the intercept was determined by the t test, as suggested by Egger, and a P value of ,0.05 was considered significant.
Software used. HWE was tested by the chi-square test using a web-based programme (http://www.ihg.gsf.de/cgi-bin/hw/ hwa1.pl). Review-Manager 4.2 and Stata 8.0 were also used in our meta-analysis. All P values were two sided.
Results
Characteristics of studies included
With our search criterion, 48 papers were found. Thirty-five papers concerning association research between eNOS and DN were identified. Among those 35 papers, 24 papers met our criteria (16) (17) (18) (19) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) and 12 papers were excluded for the following reasons: 1 paper did not provide detailed genotype information (42); 1 paper was in lack of control group data (43); 7 papers made healthy or non-diabetic nephropathy as control while we needed diabetes without nephropathy as a control group in the current meta-analysis (44-50) and 2 papers considered three genotypes in 4b/a (51, 52) . Among the 24 papers included in this meta-analysis, 17 referred to 4b/a polymorphism of eNOS. One of them had researched two geographic areas with different prevalence of DN; thus, they were treated as two independent studies (25) . Hence, the 18 papers including 3793 cases and 3161 controls were about 4b/a association. Nine eligible papers were about eNOS G894T polymorphism and one of them also had researched two areas (25) . Finally, 10 studies including 2654 cases and 1993 controls were on G894T polymorphism. For T786C polymorphism, three papers including 1348 cases and 1175 controls were considered for meta-analysis.
Finally, 18, 10 and 3 studies were respectively considered for meta-analysis concerning eNOS-4b/a, eNOS-894 and eNOS-764. Populations were categorised into Caucasian, East-Asian and others. Sixteen papers were on East-Asian population, five papers were about Caucasian population and three papers (19, 22, 23) were about other populations. All patients belonging to the control group were chosen as type 1 diabetes or type 2 diabetes without DN. Among the 24 articles included, 2 (8.3%) stated that the controls were age and gender matched (17, 28) . All articles used blood samples for genotyping assay. All the studies used poly chain reaction method of genotyping, among which six articles used polymerase chain reaction-restriction fragment length polymorphism (25%) and three articles used Taq polymerase (12.5%). Detailed characteristics of each study were listed in Table I . The numbers of patients and controls and allele frequency were also listed in Table II .
Heterogeneity
For eNOS-4b/a comparison, there was a significant heterogeneity among 18 studies with respect to association in global population under allelic genetic model (P heterogeneity 5 0.0001), recessive genetic model (P heterogeneity 5 0.01) and homozygote genetic model (P heterogeneity 5 0.06). Specifically, 'global population' indicates the population from Caucasian, EastAsian and other studies, which are using mixed ethnic group (22) or lack distinguishable population information (23) . One paper from Africa (19) was also considered as belonging to the 'other' group. We performed subgroup analyses according to ethnicity (Caucasians, East-Asian and others). In the subgroup analysis of Caucasian populations, no significant heterogeneity existed under the allelic genetic model (P heterogeneity 5 0.58), recessive genetic model (P heterogeneity 5 0.56) or homozygote genetic model (P heterogeneity 5 0.53). In the East-Asian subgroup analysis, no significant heterogeneity existed under the recessive genetic model (P heterogeneity 5 0.21) or under the homozygote genetic model (P heterogeneity 5 0.27). For eNOS-G894T polymorphism comparison, similar heterogeneity profile was found. A significant study heterogeneity existed in the global population under the allelic genetic model (P heterogeneity , 0.0001), the recessive genetic model (P heterogeneity 5 0.04) and the homozygote genetic model (P heterogeneity 5 0.02), whereas no significant heterogeneity was found in the Caucasian subgroup analysis under the allelic genetic model (P heterogeneity 5 0.99), recessive genetic model (P heterogeneity 5 0.58) or homozygote genetic model (P heterogeneity 5 0.76).
Race-specific meta-analyses Pooled OR and other results are shown in Table II . For eNOS4b/a comparison, under the RE model, the pooled OR suggested that eNOS-4b/a allele 4a was associated with an (Figure 2A ). As shown in Figure 2B , under the homozygote genetic model, a similar significant result between 4aa and the risk of DN, in comparison with eNOS-4bb, was seen in the East-Asian populations (P heterogeneity 5 0.27, FE OR 5 2.92; 95% CI 5 1.78-4.81, P , 0.0001) ( Figure 2B ) and global population (P heterogeneity 5 0.06, RE OR 5 1.61; 95% CI 5 1.06-2.46, P 5 0.03), but not in the Caucasian population (P heterogeneity 5 0.53, FE OR 5 1.01; 95% CI 5 0.67-1.54, P 5 0.95) (Table III) . A total of 10 studies were included in association investigation of eNOS-894 polymorphism and DN risk. The Caucasian and East-Asian subgroups were analysed. There was no association between the T allele and DN risk compared with the G allele in the global population (P heterogeneity 5 0.0002, RE OR 5 1.30; 95% CI 5 1.05-1.62, P 5 0.02) and in the Caucasian population (P heterogeneity 5 0.99, RE OR 5 0.91; 95% CI 5 0.79-1.03, P 5 0.14). However, an obviously significant result was observed in the East-Asian population without significant heterogeneity (P heterogeneity 5 0.27, FE OR 5 1.69; 95% CI 5 1.37-2.08, P , 0.0001) (Figure 3) . No association between eNOS-894 TT and the risk of DN was found in the global population in the recessive genetic model (P heterogeneity 5 0.06, FE OR 5 1.20, 95% CI 5 0.97-1.48, P 5 0.10) and in the homozygote genetic model (P heterogeneity 5 0.03, RE OR 5 1.18; 95% CI 5 0.80-1.74, P 5 0.40). Since the TT genotype was detected in only one study in the EastAsian population, OR of the East-Asian subgroup could not be estimated under the recessive model and homozygote contrast. 
eNOS and DN a meta-analysis
No association between eNOS-894 TT and the risk of DN was found in Caucasian population in any genetic model. Other related characteristics of the meta-analysis are shown in Table III . Only three studies were included in association investigation of eNOS-786 polymorphism and DN risk. As shown in Figure 4 , there was a weak association between the C allele and DN risk compared with the T allele in the global population (P heterogeneity 5 0.75, FE OR 5 1.17; 95% CI 5 1.01-1.37, P 5 0.04). No association between eNOS-786 CC and the risk of DN was found in the global population in the recessive genetic model (P heterogeneity 5 0.004, RE OR 5 1.86, 95% CI 5 0.70-4.92, P 5 0.21) and in the homozygote genetic model (P heterogeneity 5 0.02, RE OR 5 1.82; 95% CI 5 0.76-4.33, P 5 0.18).
Sensitivity analyses
With regard to eNOS-4b/a polymorphism, the resulting pattern was not changed by any single study in every whole and subgroup (data not shown). A similar sensitivity analysis was also performed in comparisons of eNOS-G894T and T786C that the pooled OR (including 95% CI) pattern was consistently not changed in all contrasts when each single study was excluded.
Publication bias
Egger's linear regression tests were performed to statistically evaluate the funnel plot symmetry. The P value of G894T was 0.058, which means there was no significant publication bias in the analysis of eNOS-894 polymorphism, whereas the P value of 4b/a and T786C was, respectively, 0.004 and 0.034, which indicated that there was significant publication bias in the analysis of eNOS-4b/a and eNOS-786 polymorphisms.
Discussion
In the present meta-analysis, a significant association between DN and eNOS polymorphisms was observed in the global population. Such association appears to be enhanced when subgroup studies were performed among Asian ethnics. According to those results, we conclude that eNOS would be considered as an effective genetic factor, which contributed to the pathology of DN. This conclusion is consistent with published functional research of the eNOS gene. It was reported that endothelial dysfunction may cause an uncoupling of the vascular endothelial growth factor (VEGF)-endothelial nitric oxide (eNO) axis, resulting in increased levels of VEGF and excessive endothelial cell proliferation (53,54). Thus, the maintenance of VEGF-eNO coupling was deemed to have an important role in advanced DN in many cases (55, 56) . As a well-characterised enzyme which is responsible for eNO level, eNOS may be functionally related to DN pathology. Furthermore, such hypothesis was demonstrated in eNOS knock-out mice model (57) .
Notably, three candidate polymorphisms show a similar trend of the susceptibility to DN. This may lead us to the functional research of each variant site. G894T polymorphism is located in exon 8, which leads to a single amino acid substitution from glutamate to aspartate at the 298 site. Shear is a key modulator of NOS3 function in vivo and association with caveolae is important for the control of NOS3 protein activity. Basal caveolar membrane enrichment and enzyme function investigation indicated a genotype-dependant alteration in basal and shear-induced activation, as well as an altered caveolar localisation and consequent impairment in the co-ordination of the regulatory cycle of the eNOS enzyme (58) . Most of the studies on the 4b/a variants function reveal a minimal difference between each genotype. This is perhaps due to the non-coding location of this polymorphism. However, there is also a report which suggested that this variant contributes to basal levels of plasma NO (12) . Thus, we cannot exclude the possibility of 4b/a variable number of tandem repeats as a functional significant factor to DN risk. T786C polymorphism is located in the promoter of the eNOS gene at the eNOS-786 site. Molecular exploration indicated that the replacement of thymidine by cytosine is able to cause a reduced promoter activity, which leads to a compromised production of the eNOS enzyme in vivo (59, 60) . All the reports mentioned indicated that the minority genotypes of the polymorphisms under investigation would cause a considerable change in the eNOS enzyme, either in activity or in production, and such a change may contribute to the abolishment of proper eNO level in a diabetic environment. Further study of animal models may be helpful to validate the mechanism by which the susceptibility to DN is modulated by eNOS variants. According to the current data, there is an increased risk among minority genotype Asian carriers. This phenomenon may be ascribed to different reasons. First of all, the CIs for effect sizes in both Caucasian and East-Asian populations overlapped with each other; thus, it is possible that the effect of eNOS variants to the DN pathology is similar between different populations, However, the present data from Caucasian association studies (patients/controls 2518/1947) are statistically insufficient so as to detect such similarity. Secondly, the genetic heterogeneity may contribute to such discrepancy. According to Table III, the frequency of each genotype shows a significant difference among populations, such a heterogeneity may statistically contribute to the discrepancy of pooled OR. Finally, the incidence of DN increased sharply in Asians as compared with other populations, which suggested a distinguishable background of pathology in the Asian population (61, 62) . Such background may be genetic like different linkage maps or due to different lifestyle or public sanitation. Further enthnic-specific association studies are needed to elucidate the population discrepancy of DN susceptibility.
To date, there are two methods for the control population concerning diabetic complications association studies, one using healthy control and the other with diabetic patients who do not suffer from complications. Apparently, the endogenous environment of diabetic patients has distinct features that contribute to the pathology and progression of DN. Thus, we propose that diabetic patients without DN will serve as a better control to study the effect of eNOS polymorphisms. First of all, it reported that patients with diabetes have higher risk to diabetic complications (63) . Therefore, if a comparison was conducted between DN patients and healthy individuals rather than diabetic controls, then the OR for each eNOS variant will inevitably be increased. Moreover, because we focus on the effect of genetic polymorphisms on DN pathology, it is important to maintain different genotype carriers to have a similar background. One of the important features of diabetes is the intracellular hyperglycaemia during the early course, decreased activity of vasodilators such as NO, increased activity of vasoconstrictors such as angiotensin II and endothelin-1 and elaboration of permeability factors such as VEGF. Such extracellular matrix dysfunctions would lead to the abnormalities in blood flow and increased vascular permeability (64) . Last but not the least, hyperglycemia is related to the activation of protein kinase C (PKC), which will inhibit the insulin-stimulated expression of eNOS (65) . And this would have an effect on the research of eNOS polymorphism. Therefore, association studies with healthy controls were excluded in the current meta-analysis. Nevertheless, better study designs are needed to validate the significance of difference between healthy controls and diabetic controls.
As other researchers reported, the progression of DN is related to the dysfunction of the endothelial cell, whose initiation and maintenance are closely connected to the eNOS/ NO system (66) . And for a long time, antioxidant therapy is deemed an effective solution for diabetic complications. For instance, it is reported that statins, an ACE inhibitor, which has a strong intracellular antioxidant activity, may play an important role in antioxidant therapy in diabetic complications such as DN. In addition, statins increase NO bioavailability and decrease superoxide production, interfering with NADPH activity and modulating eNOS expression (67) . Meanwhile, PKC beta inhibitor is also identified as potential therapy to DN (68) . Also, activation of the PKC beta isoform is closely linked to diabetes and decreased bioavailability of NO in endothelial cells. PKC beta over-expression suppressed eNOS in bovine endothelial cells (69) . Therefore, it would be of interest to explore the different response to therapy among eNOS variants carriers in future research.
Egger's linear regression analysis indicated that there is a significant publication bias in this meta-analysis. According to the funnel plots, most of the publication bias comes from two papers (33, 40) . These two papers used samples from a population of middle-north China with a relative small size. This suggests publication bias with the smaller studies being published only if they show a significant effect. It is also possible that the susceptibility to DN has a different trend in this region. Comprehensive interpretation is hard to make due to the lack of sufficient area-specific data. Moreover, as indicated by the sensitivity analysis, omitting any single study will not change the significant of pooled results. We conclude that the association between eNOS polymorphisms and DN will not be undermined by publication bias.
In conclusion, an increased susceptibility of eNOS gene 4a (4b/a), T (G894T) and C (T786C) variant carriers to DN was observed in the present meta-analysis. Similar trends were enhanced in the Asian subgroup study. An ethnic-specific association study is needed for further research. 
